Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D Cohen; Luciano J Costa; Madhav V Dhodapkar; Francesca Gay; Nicole Gormley; Damian J Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C Pasquini; Noemi Puig; G David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A Shah; Qian Shi; Andrew Spencer; Vera J Suman; Saad Z Usmani; Philip L McCarthy

doi:10.1016/j.bbmt.2020.06.011

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255. doi: 10.1016/j.bbmt.2020.06.011. Epub 2020 Jun 24.

Authors

Sarah A Holstein¹, Alan Howard², David Avigan³, Manisha Bhutani⁴, Adam D Cohen⁵, Luciano J Costa⁶, Madhav V Dhodapkar⁷, Francesca Gay⁸, Nicole Gormley⁹, Damian J Green¹⁰, Jens Hillengass¹¹, Neha Korde¹², Zihai Li¹³, Sham Mailankody¹², Paola Neri¹⁴, Samir Parekh¹⁵, Marcelo C Pasquini¹⁶, Noemi Puig¹⁷, G David Roodman¹⁸, Mehmet Kemal Samur¹⁹, Nina Shah²⁰, Urvi A Shah¹², Qian Shi²¹, Andrew Spencer²², Vera J Suman²¹, Saad Z Usmani⁴, Philip L McCarthy¹¹

Affiliations

¹ University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: [email protected].
² Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
³ Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁴ Levine Cancer Institute, Charlotte, North Carolina.
⁵ Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
⁶ University of Alabama at Birmingham, Birmingham, Alabama.
⁷ Winship Cancer Institute of Emory University, Atlanta, Georgia.
⁸ Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
⁹ US Food and Drug Administration, Silver Spring, Maryland.
¹⁰ Fred Hutchinson Cancer Research Center & Seattle Cancer Care Alliance, Seattle, Washington.
¹¹ Roswell Park Comprehensive Cancer Center, Buffalo, New York.
¹² Memorial Sloan Kettering Cancer Center, New York, New York.
¹³ The Ohio State University, Columbus, Ohio.
¹⁴ University of Calgary, Calgary, Alberta.
¹⁵ Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁶ Medical College of Wisconsin, Milwaukee, Wisconsin.
¹⁷ Institute for Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain.
¹⁸ Indiana University School of Medicine, Indianapolis, Indiana.
¹⁹ Dana-Farber Cancer Institute, Boston, Massachusetts.
²⁰ University of California San Francisco, San Francisco, California.
²¹ Mayo Clinic, Rochester, Minnesota.
²² Alfred Hospital-Monash University, Melbourne, Victoria.

Abstract

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled "Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma." This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.

Keywords: CAR T cell; Endpoint; Immune profiling; Minimal residual disease; Multiple myeloma.

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding